Sermorelin vs. Ipamorelin vs. CJC-1295: What the Evidence on Growth-Hormone Secretagogues Actually Shows

Telehealth clinics sell sermorelin, ipamorelin, and CJC-1295 as interchangeable members of a category — "GH peptides," "growth hormone secretagogues," sometimes just "GH boosters" — and the pitch is usually the same regardless of which one lands in the vial: more lean mass, better sleep, slower aging, a gentler alternative to injecting growth hormone itself. The question most people actually type is a two-way one — sermorelin vs ipamorelin — and the framing is already wrong before the comparison starts, because it assumes they are two flavours of the same thing. They are not. These three compounds don't share a mechanism, don't share a regulatory history, and don't share an evidence base. Two of them work through one receptor; the third works through a completely different one. This is a companion to our sermorelin provider rankings, which grade who sells this class of compound and how honestly — this article is about what the compounds themselves are actually shown to do.

Two receptors, not one

Sermorelin and CJC-1295 are both GHRH analogs — truncated or re-engineered versions of growth-hormone-releasing hormone, the signal the hypothalamus itself uses to tell the pituitary to release GH. CJC-1295 was built specifically to fix GHRH's biggest practical problem: natural GHRH and sermorelin (a 29-amino-acid fragment of it) are cleared from the body within minutes, so the lab that developed CJC-1295 modified the molecule to resist that breakdown and bind serum albumin, extending its action from minutes to days¹.

Ipamorelin is not a GHRH analog at all. It's a ghrelin-receptor agonist — a small pentapeptide that activates the same "GHRP-like receptor" ghrelin itself binds, a mechanistically distinct pathway from the GHRH receptor. The peptide's own discovery paper describes it as the first such compound shown to be selective: in pigs, doses more than 200-fold above what triggered GH release did not raise cortisol or ACTH the way older ghrelin-receptor compounds (GHRP-6, GHRP-2) did in the same experiments². That selectivity claim is real and well-documented — but it comes from pituitary cells, anesthetized rats, and conscious pigs, not from a controlled human trial measuring anything past a hormone level.

Sermorelin's actual evidence base is a pediatric drug

Sermorelin has the longest track record of the three, and it is almost entirely a pediatric one. The compound's own clinical-review literature is titled, plainly, around "the diagnosis and treatment of children with idiopathic growth hormone deficiency"³ — that was the population sermorelin was developed and evaluated in. The FDA's own drug-approval database confirms this history directly: sermorelin acetate was approved under the brand name Geref in 1990, then granted orphan-drug status in 1997 for a new dosage form — orphan designations exist specifically for rare-disease indications, and pediatric GHD is one. Geref's marketing status today is "Discontinued," with FDA's own database carrying the note that the discontinuation was not for safety or effectiveness reasons — the product was simply pulled from commercial production⁴.

None of that is evidence against sermorelin working as a GHRH agonist; it plainly does. It's evidence about who it was studied in. The population telehealth companies sell it to today — healthy or midlife adults without a diagnosed pituitary condition, chasing body composition or energy — is not the population that generated sermorelin's approval history. The closest thing to real-world data in that adult population is thin: a 2017 retrospective chart review of 105 men already on testosterone therapy, of whom only 14 met strict inclusion criteria, prescribed a combination of sermorelin and two other GH-releasing peptides (GHRP-2, GHRP-6) together — not sermorelin alone. IGF-1 levels rose significantly over a mean 134 days of treatment, but the design was retrospective, uncontrolled, and combined three different secretagogues into one regimen, which means it cannot isolate what sermorelin itself contributed⁵. A 2020 review of GH secretagogues in hypogonadal men reaches a similar note of caution about the broader class: real interest, real biological plausibility, but a published evidence base that is small and mostly short-term⁶. For what timeline that thin evidence base actually supports — and a plain separation of what's measured from what's anecdotal — see our companion piece walking through the sermorelin before-and-after data.

CJC-1295: real biomarker data in healthy adults, over weeks — not outcome data

CJC-1295 has the best-controlled human data of the three, and it's worth being precise about exactly what that data does and doesn't show. The compound's foundational human trial was two randomized, placebo-controlled, double-blind, ascending-dose studies — 28 and 49 days long — in healthy adults aged 21 to 61. A single injection produced dose-dependent increases in GH (2- to 10-fold) sustained for six or more days, and in IGF-1 (1.5- to 3-fold) for nine to eleven days; the estimated half-life was 5.8 to 8.1 days, and after repeated dosing IGF-1 stayed elevated for up to 28 days. No serious adverse reactions were reported, and effects appeared most favorable at 30 or 60 micrograms/kg⁷.

That is genuinely strong evidence that CJC-1295 does what a long-acting GHRH analog is supposed to do: raise and sustain GH and IGF-1 in people who are not growth-hormone deficient. It is not evidence that raising those biomarkers for a few weeks changes body composition, strength, sleep quality, or aging over months or years — the trial wasn't designed to measure any of that, and the citation above is the trial, not a paraphrase of one. Telehealth copy that cites "clinical studies" for CJC-1295's wellness effects is, at best, extrapolating from a pharmacodynamics trial to outcomes that trial never tested.

Ipamorelin: solid mechanism, thin and mixed human evidence

Ipamorelin does have some human data, and it's worth separating the two studies that exist from the marketing claims layered on top of them. A 1999 dose-escalation pharmacokinetic study in eight healthy male volunteers per dose level confirmed the mechanism translates to people: intravenous ipamorelin triggered a single, time-limited pulse of GH release, peaking around 40 minutes after infusion and clearing with a short (roughly 2-hour) half-life⁸. That establishes ipamorelin raises GH acutely in humans — a real, useful, and narrow finding.

The one randomized, placebo-controlled human trial of ipamorelin that tested an actual clinical outcome is not about muscle, fat, or aging at all. It's a 2014 multicenter phase 2 trial of intravenous ipamorelin for postoperative ileus — sluggish bowel function after abdominal surgery — in 114 hospitalized surgical patients, based on ghrelin receptors' separate role in gut motility. The primary endpoint was time to tolerating a solid meal after surgery: 25.3 hours with ipamorelin versus 32.6 hours with placebo, a difference that did not reach statistical significance (p = 0.15)⁹. That is the only ipamorelin trial in the published literature with a real clinical endpoint and a placebo arm, and it missed. FDA's own reviewers reached the same read when they later evaluated ipamorelin for compounding purposes: citing that same 2014 trial, FDA concluded there are "no data to support the effectiveness of ipamorelin ... for the proposed [subcutaneous] route of administration" for either growth-hormone deficiency or postoperative ileus¹⁰. A search of the wider literature for anything resembling a controlled trial of ipamorelin for body composition, fat loss, or anti-aging in adults returns nothing — what exists instead is a body of analytical-chemistry and anti-doping-detection papers that use ipamorelin as a reference compound for screening methods, not clinical trials of the peptide itself. For a narrower, direct read on how ipamorelin's evidence stacks up specifically against sermorelin's — rather than this article's three-way survey — see our dedicated ipamorelin vs. sermorelin comparison.

None of the three are FDA-approved for what telehealth sells

Sermorelin's only FDA-approved product, discussed above, is discontinued and was approved for pediatric GHD — not adult wellness, longevity, or body composition. Ipamorelin and CJC-1295 have no FDA-approved drug product at all. FDA's own compounding reviewers state this outright: their briefing document on ipamorelin notes plainly that med spas and wellness clinics market it "likely" as a compounded product "because there are no FDA-approved drug products containing ipamorelin (free base) or ipamorelin acetate"¹⁰. A direct, independent check against DailyMed — the National Library of Medicine's official archive of FDA-approved drug labeling — confirms the same thing for both compounds: zero results for either "ipamorelin" or "CJC-1295"¹¹¹². That is a meaningfully different regulatory status than tirzepatide's, which is FDA-approved and merely subject to a narrowed compounding exception — see our tirzepatide provider comparison if that's the category you're actually shopping. Consistent with all of this, when FDA's Pharmacy Compounding Advisory Committee formally took up CJC-1295 (in every salt and conjugated form nominated) for possible inclusion on the 503A compounding-bulks list in December 2024, FDA's own staff proposed, item by item, that none of those forms be included¹³.

Not under active FDA compounding review, either

FDA maintains a running, dated list of substances nominated for its 503A compounding-bulks list, sorted into three categories: substances under active evaluation (Category 1), substances that raised significant safety concerns (Category 2), and substances nominated without adequate supporting information (Category 3). Reading FDA's own current version of that list — updated May 14, 2026 — none of sermorelin, ipamorelin, or CJC-1295 appear in any of the three categories¹⁴. A related compound, ibutamoren, better known by its research name MK-677 (a different, orally active, non-peptide ghrelin-receptor agonist sometimes sold alongside these three), does sit in Category 2 over safety concerns — a real distinction from the three compounds this article covers, and one with an actual clinical-trial safety record behind it, not just a listing — and two older GH-releasing peptides, GHRP-2 and GHRP-6, sit in Category 3. Sermorelin, ipamorelin, and CJC-1295 simply aren't on FDA's active-review radar under this specific process at all — consistent with the committee having already been advised against listing them. A pharmacy compounding them today isn't operating inside an FDA "under evaluation, enforcement discretion pending" category the way some other compounded peptides are; it's operating in the older, more general 503A/503B framework, with none of these three named as bulk substances the agency currently evaluates one way or the other.

Banned in tested sport, all three, by name

If you're weighing any of these for athletic performance rather than general wellness, this part is unambiguous. WADA's 2026 Prohibited List — the actual document, not a summary of it — lists growth hormone-releasing factors under category WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), specifically subsection S2.2.4, "Prohibited at all times," as a non-Specified Substance class. The list names CJC-1295 and sermorelin explicitly under "growth hormone-releasing hormone (GHRH) and its analogues," and names ipamorelin explicitly under "growth hormone secretagogues (GHS) and their mimetics" — a separate line from the GHRH analogs, matching the mechanistic split described above¹⁵. All three are banned in and out of competition, with no dose threshold or therapeutic-use exemption built into the class itself. If you're tested under any WADA-code sport, none of these three peptides is a gray area.

What the evidence actually supports — and what it doesn't

Stripped of marketing language: sermorelin has a real, decades-old evidence base for raising GH via the GHRH receptor — generated almost entirely in children with diagnosed growth-hormone deficiency, with only thin, uncontrolled, combination-therapy data in adults without that diagnosis. CJC-1295 has genuinely strong human biomarker data — a real placebo-controlled trial confirming sustained GH/IGF-1 elevation in healthy adults — but no published trial testing whether that translates into the body-composition or longevity outcomes it's marketed for. Ipamorelin has a confirmed human mechanism and exactly one placebo-controlled outcome trial in the literature, for an unrelated surgical-recovery indication, which missed its primary endpoint. None of the three is FDA-approved for adult wellness use, none currently sits under active FDA compounding evaluation, and all three are prohibited by name in tested competitive sport.

That absence of approval has a consequence people rarely connect to it: with no current FDA label for any of the three, there is also no FDA-reviewed adverse-reaction section for any of them. Our look at what sermorelin's side-effect evidence actually consists of works through what fills that gap — its own trials' tolerability data, 58 reports in FDA's adverse-event database, and the labelled warnings carried by tesamorelin, the one drug in this class still marketed, including an explicit neoplasm warning that answers the cancer question this category attracts.

How the providers we've reviewed compare

Of the providers our sermorelin rankings currently cover, eighteen actually sell sermorelin. Precision Telemed names its compounding pharmacy and states a federal regulatory category for it in writing, though its advertised sermorelin price steps up after the first month. Empower Pharmacy is not a telehealth reseller at all — it's the compounding pharmacy itself, and states its own 503A/503B status more directly than any of the others — but it fills a prescription you already have rather than writing one, and publishes no public price. Fridays names four separate partner pharmacies directly in its own Terms & Conditions — tied with EOS Health for the most of any reseller here — and states a 503A category covering all of them, though not on the product page itself the way Precision Telemed names Rush Pharmacy. EOS Health, for its part, names five pharmacies on a dedicated Clinical & Pharmacy Partners page and states the 503A category again directly on its own sermorelin product page, at a flat $120/month with no plan-tier selector — but its own Terms & Conditions and HIPAA Privacy Policy pages disagree with each other about whether HIPAA applies to the company at all, even as it markets "HIPAA-Compliant Care" sitewide. Liberty is the only provider on this list stating a 503B — rather than 503A — regulatory category anywhere on its site, at a flat $116/month for sermorelin; but that claim lives on its general FAQ and trust bar, not its sermorelin product page specifically, and its own site's product data shows no compounding disclosure at all for sermorelin, the same treatment it gives its plain FDA-approved metformin tablet. StackMD names no pharmacy at all — its Platform Disclosure page hedges dispensing between 503A pharmacies and 503B outsourcing facilities without resolving to one — and prices sermorelin by supply length rather than dose: a real $175/month for a 4-Week Supply that its own shop data and homepage banner agree on, undercut by its own separate /sermorelin/ marketing page, which advertises a lower, unmatched "$135" that corresponds to no actual product on the site. CoreAge Rx advertises the lowest sermorelin floor of the group but names no pharmacy and publishes no price ceiling above that floor. NuBloom prices its own /sermorlin/ page at a flat $249/month — no prepay tier, no dose breakdown — but is the only provider here whose product page never uses the word "compounded" at all for this product, even though its own semaglutide and tirzepatide pages both do; it names no pharmacy and states no 503A/503B category either. Lttl states, in its own words, a real $199/month standing sermorelin rate — but not on the /longevity/sermorelin product page itself, which instead headlines a lower "From $129" figure that its own site-wide pricing data reveals is the 12-month prepay tier, not the no-commitment monthly price. Unlike NuBloom's sermorelin page, Lttl's does use the word "compounded" directly. It names four partner pharmacies (RedRock Pharmacy, Health Warehouse, Precision Compounding Pharmacy, Triad Rx) in its own Terms of Service but, like Fridays and Trinity Meds above, states no 503A/503B category for any of them. Eden sells a real Sermorelin Injection product and names its own compounding pharmacy directly (edenpharmacy.com, a real acquisition confirmed by a linked press release) — but publishes no standing month-to-month price for it anywhere on the site, only an asterisked "First month as low as $126" tied to a 3-month prepay plan; even its own dedicated "Sermorelin Cost" educational article gives generic market ranges rather than Eden's own number. Strut Health is the only provider here selling a genuine oral, needle-free sermorelin format — a lozenge/troche headlined at $99/mo, alongside a $119/mo injectable — but neither product page discloses a one-time (non-auto-refill) price anywhere in dollars; only Strut's own blog acknowledges the headline is a discounted subscription rate at all, stating a blanket "21% off" figure that doesn't even match the "Save 18%" badge printed on the injectable product page itself. Strut Health also carries a real, dated FDA warning letter (Feb 2026) over how it marketed its compounded tirzepatide and semaglutide elsewhere on the same site — see its review for the full finding. Hone Health sells no tirzepatide at all (its GLP-1 offering is branded Zepbound through LillyDirect, not a compounded product) — its own sermorelin pages state twice, in its own words, "This is a compounded product and has not been approved by the FDA," at a headlined "$130/mo + membership" that the page's own markup ties to its $155/month Premium tier without naming it, for a true $285/month standing cost. BluefitMD is the newest addition here, and unlike Hone Health it sells both compounds — its own /sermorelin page states plainly, "This product has not been evaluated by the FDA," at a genuinely undisguised $249/month standing price that its own product page and its own checkout funnel agree on (a cleaner story than BluefitMD's own tirzepatide listing, where the true price more than doubles by dose against a $225/mo prepay headline); it also carries its own dated FDA warning letter (Feb 20, 2026) over how it marketed compounded tirzepatide and semaglutide elsewhere on the same site — see its review for the full finding, including a LegitScript badge that fails to resolve at LegitScript's own CDN. Ivim Health is selling a sublingual (not injectable) sermorelin format — its own /sermorelin/ page states the required "$75/mo Membership" directly beside the $129 medication price, a more transparent disclosure than its own tirzepatide listing's small-print footnote, for a combined $204/mo. Unlike its own tirzepatide page (which does state, unhedged, that the medication is "not FDA-approved"), Ivim's /sermorelin/ page carries no such disclaimer anywhere — a real, product-specific gap in an otherwise-disclosed site. It too carries its own dated FDA warning letter (Feb 20, 2026, MARCS-CMS 721816) over the same mislabeled-compounder finding on its compounded tirzepatide product — its own LegitScript seal, unlike BluefitMD's, actually resolves (HTTP 200) — and a real self-contradiction between its own Terms and Membership Agreement over whether Michigan or Ohio law governs the company; see its review for the full finding. Viv Health is the newest addition here, selling a "Sermorelin Injection" headlined "Starting At $245" with no dose tiers and, unusually for this board, no stated billing cadence on the price itself. Unlike Ivim's sermorelin page, Viv's DOES carry the same "not reviewed or approved by the FDA" disclaimer its tirzepatide and semaglutide pages do — a shared disclaimer block rendered identically across all three, closing the exact product-specific gap Ivim's site leaves open. That same shared block is also where the site's real issue shows up: it answers a nearby pricing FAQ by naming a different company ("Eden offers a comprehensive package...") instead of Viv Health, and a reused testimonial separately names its own actual white-label checkout vendor, CareGLP, by name — a live copy-paste artifact this review found independent of Viv's own dated FDA warning letter (Feb 20, 2026, MARCS-CMS 721818, the same single-issue template as Ivim's); see its review for the full finding. Kin Meds is the newest addition here, selling a compounded Sermorelin injection headlined "Starts At $349" for a 30-day supply at one flat price — no dose tiers found anywhere on the page. Its own FAQ states it "works exclusively with Rush Pharmacy," but its own Returns and Refund Policy separately lists a second, different pharmacy (Strive Pharmacy) as the return address for the same prescription medication — an unresolved first-party contradiction this review found independent of its own dated FDA warning letter (Feb 20, 2026, MARCS-CMS 721450, the same mislabeled-compounder template as the others, plus two separately-cited marketing claims implying FDA approval). Two more added from a second round of Katalys partner research show a different shape of sourcing gap. Synergy Rx states a real, findable "Sermorelin Injection — Starting at $275" price with no prepay trap, but its own marketing claims "all 50 U.S. states" while its own Terms of Use directly contradict that, stating the real state list isn't published and must be requested by email — a first-party contradiction between the company's own marketing and its own binding legal terms. Telos Rx names its secondary pharmacy with a genuinely specific, sourced 10-state exclusion list, better than most peers here, but its own "as low as $125" headline sits beside a $299 "compare" price captioned "Your price depends on plan length" that the site never confirms is an actual 1-month rate. One more, from a continuation of that same Tier 2 research round: Big Easy Weight Loss individually names six pharmacies on its own /pharmacy-partners page, each with its own stated 503(a)/503(b) category and its own state-exclusion list — the most granular per-pharmacy disclosure in this whole batch — but its own dedicated sermorelin product page states only "Starting at $267 / 8 week plan," never a monthly rate, and the same $267 figure is bundled with NAD+ on the site's own /treatment-pricing page even though the dedicated product page prices sermorelin alone; several of this board's other rows — EOS Health, Fridays, and Lttl among them — sell NAD+ as a genuinely standalone product instead, covered separately on our NAD+ provider comparison. PlexusDx, Fridays, EOS Health, StackMD, Lttl, Eden, Strut Health, Hone Health, BluefitMD, Viv Health, Kin Meds, and Big Easy Weight Loss are the twelve telehealth resellers here that state outright, in their own words, that compounded medications aren't FDA-approved — a disclosure both CoreAge Rx and Liberty leave unstated for sermorelin specifically, even though neither would need to make the claim to be accurate, since neither states one either way for this product. NuBloom is a stranger case than either: a correct "not FDA-approved" disclaimer exists elsewhere on its site, but its own FAQ separately and unhedged claims its GLP-1s ARE "FDA-approved" — a live, uncorrected contradiction on the same domain, detailed in its review. Five more joined the roster in a later Katalys research round, each re-verified live rather than trusted from the research doc. Jently names its pharmacy AND its 503A category in one sentence and discloses its real "MONTHLY RETAIL PRICE" ($199) on the same page as its 3/6/12-month prepay tiers — a transparent same-page disclosure, the cleanest of this batch. FitFlow sells a real Sermorelin Injection with a 5mL vial and homekit included, headlined "Save $25 on your first order — $175" — the arithmetic implies a $200 standing price the site never states directly in dollars. GobyMeds prices sermorelin at a single, flat $199/month with no dose tiers, undercut by a sitewide promo banner naming an offer end-date that had already passed. ReadyRx silently auto-applies a discount coupon to every visitor by default; the true standing $225/month rate was confirmed only by querying its own live pricing API directly, alongside an oral/ODT sermorelin form the injectable-only peers here don't offer. RxION Health sells a single, flat "Monthly Supply, $299/mo" with no prepay tiers for this product — unlike its own tirzepatide and semaglutide listings — and its LegitScript badge links to a generic keyword search rather than a checkable seal. Twelve more providers on our tirzepatide board — yourEra, Found, Henry Meds, Welling Health, Rejuve Meds, Rivo Health, Transparent Meds, Trinity Meds, Voxy, Kova, Willow, NexLife, and 24HrDoc — don't sell sermorelin at all; their catalogs are tirzepatide (and, for some, semaglutide) only, a different drug class entirely (an FDA-approved GLP-1/GIP receptor agonist, not a GH secretagogue). Rivo Health's own homepage is worth flagging specifically here: it markets "Sermorelin injections" and "Sermorelin orals" prominently under a "Longevity" section, but no purchase link or checkout offering code for either exists anywhere we could find — marketed, not actually for sale, per its own review. Transparent Meds does the same thing at smaller scale: its own product-info modal carries full Sermorelin dosing and safety copy, styled identically to its three actually-purchasable products, but that entry's own "Get Started" button routes to a contact form rather than a checkout offering code. Voxy takes the same non-sale further than either: its own dedicated /sermorelin landing page carries a full marketing narrative — hero, benefits, FAQ, testimonials — but the page's pricing section isn't merely unlinked or hedged as "coming soon" in its copy, it's a literal HTML comment in the live page's own rendered source, placeholder "$XXX" tokens and all, with a developer's own note left in: "NOTE TO EDITOR: replace all $XXX... before scaling spend." Their own reviews and our tirzepatide comparison are the more relevant reads if that's the category you're actually in the market for. For a direct, synthesized verdict on whether sermorelin itself is safe — rather than this article's own comparative read across three compounds — see our answer to that question. Once a prescriber has actually given you a sermorelin dose in milligrams, our reconstitution calculator converts that into the exact syringe volume and insulin-syringe units it corresponds to.